eHealthMe - Personalized health information & community eHealthMe - Personalized health information & community

Personalized health information & community

  Tools   Community
All drugs: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
All conditions: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Check symptoms       Compare drugs       Ask question       Write review       Answered/ Unanswered       Reviews

From FDA reports: drug interactions between Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine for a Female patient aged 56

This is a personalized study for a 56 year old female patient. The study is created by eHealthMe based on reports of 2 people who take the same drugs and have drug interactionsfrom FDA.

On Dec, 20, 2014: 2 people who reported to have interactions when taking Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine are studied

Trend of Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine's drug interactions, side effects, and effectiveness reports (3475256)

Information of the patient in this study:

Age: 56

Gender: female

Conditions: Adenocarcinoma Pancreas

Drugs taking:
- Sorafenib: used for < 1 month
- Gemcitabine: used for < 1 month
- Sorafenib: used for < 1 month
- Sorafenib: used for < 1 month
- Gemcitabine: used for < 1 month
- Gemcitabine: used for < 1 month
- Midazolam Hcl: used for < 1 month
- Meperidine: used for < 1 month
- Glucagon: used for < 1 month
- Promethazine: used for < 1 month

Drug interactions have: Thrombocytopenia, Haemoglobin Decreased, Gastrointestinal Perforation, Dyspnoea, Diverticulitis

eHealthMe real world results:

Comparison with this patient's adverse outcomes among females aged 56 (±5):

InteractionNumber of reports
Thrombocytopenia (decrease of platelets in blood)2 (100.00%)
Haemoglobin Decreased2 (100.00%)
Gastrointestinal Perforation (hole in the digestive tract)2 (100.00%)
Dyspnoea (difficult or laboured respiration)2 (100.00%)
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)2 (100.00%)

Most common interactions experienced by females aged 56 (±5) in the use of Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine:

InteractionNumber of reports
Thrombocytopenia (decrease of platelets in blood)2
Haemoglobin Decreased2
Gastrointestinal Perforation (hole in the digestive tract)2
Dyspnoea (difficult or laboured respiration)2
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)2

Most common interactions experienced by females aged 56 (±5) in long term use of Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine:

None.

For people in general (regardless of gender or age):

Comparison with this patient's adverse outcomes:

InteractionNumber of reports
Thrombocytopenia (decrease of platelets in blood)2 (100.00%)
Haemoglobin Decreased2 (100.00%)
Gastrointestinal Perforation (hole in the digestive tract)2 (100.00%)
Dyspnoea (difficult or laboured respiration)2 (100.00%)
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)2 (100.00%)

Most common interactions experienced by people in the use of Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine:

InteractionNumber of reports
Thrombocytopenia (decrease of platelets in blood)2
Haemoglobin Decreased2
Gastrointestinal Perforation (hole in the digestive tract)2
Dyspnoea (difficult or laboured respiration)2
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)2

Most common interactions experienced by people in long term use of Sorafenib, Gemcitabine, Midazolam Hcl, Meperidine, Glucagon, Promethazine:

None.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

You can also:

Comments from related studies:

  • From this study (5 years ago):

  • Starting 3rd cycle (6th infusion) after loss of breath determined to be congestive heart failure and medication modified by cardiologist. Second day after spent in bed with apathy and no appetite. This is different from prior infusions.

    Reply

Can you answer these questions (Ask a question):

More questions for: Adenocarcinoma Pancreas, Diverticulitis, Dyspnoea, Gastrointestinal Perforation, Gemcitabine, Glucagon, Haemoglobin Decreased, Promethazine, Thrombocytopenia

You may be interested at these reviews (Write a review):

  • Diverticulitis and pain/swellingin lower extremities
    When ever I have had a bout of diverticulitis not only do I experience the normal symptoms but both me ankles and feet will swell to the point of being unrecognizable.I also have severe pain in my knnes. To the point where I cannot bend or hold my weight I mentioned this ? to md he wrote it off. Why ...
  • Faslodex driven hell
    I have metastatic breast cancer...which has spread to my bones. Needless to say...I'm not a happy camper. Faslodex was my oncologist’s drug of choice for me. I've been on it since July 28, 2014....My first month was loading dosage...and each month that has followed I receive two injections in m ...
  • Bone infections involving my teeth crohns and prednisone over the past 12 years
    Dentist [2] tell me the abscesses are in the bones and I've had several root canals, bridges, bone surgeries that last 3 years, teeth became so mobile after the bone economy I had them pulled and now a partial one month ago. Bone loss etc. I don't have the ridges in my mouth that most Crohn patients ...

More reviews for: Adenocarcinoma Pancreas, Diverticulitis, Dyspnoea, Gastrointestinal Perforation, Gemcitabine, Glucagon, Haemoglobin Decreased, Promethazine, Thrombocytopenia

Complete side effects:

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

   

About - Terms of service - Privacy policy - Press - Testimonials - Contact us

 
© 2015 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.